{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:03:37Z","timestamp":1740107017532,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00432-021-03607-5","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T11:08:27Z","timestamp":1619089707000},"page":"3693-3698","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Economics influences therapy decisions in chronic myeloid leukaemia: should it?"],"prefix":"10.1007","volume":"147","author":[{"given":"Qian","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-1676","authenticated-orcid":false,"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,22]]},"reference":[{"issue":"s3","key":"3607_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/hec.3628","volume":"26","author":"A Arrieta","year":"2017","unstructured":"Arrieta A, Garcia-Prado A, Gonzalez P, Pinto-Prades JL (2017) Risk attitudes in medical decisions for others: An experimental approach. Health Econ 26(s3):97\u2013113","journal-title":"Health Econ"},{"issue":"Suppl 2","key":"3607_CR2","doi-asserted-by":"publisher","first-page":"S249","DOI":"10.1007\/s00277-015-2319-x","volume":"94","author":"RM Conti","year":"2015","unstructured":"Conti RM, Padula WV, Larson RA (2015) Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU. Ann Hematol 94(Suppl 2):S249\u2013S257","journal-title":"Ann Hematol"},{"issue":"6","key":"3607_CR3","doi-asserted-by":"publisher","first-page":"e304","DOI":"10.1016\/j.clml.2020.01.009","volume":"20","author":"X Dou","year":"2020","unstructured":"Dou X, Qin Y, Lai Y, Shi X, Jiang Q (2020) Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in patients with newly diagnosed chronic myeloid leukemia with a consideration of socioeconomic characteristics: A retrospective study from a single center. Clin Lymphoma Myeloma Leuk 20(6):e304\u2013e315","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3607_CR4","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.athoracsur.2017.01.066","volume":"104","author":"MK Ferguson","year":"2017","unstructured":"Ferguson MK, Huisingh-Scheetz M, Thompson K, Wroblewski K, Farnam J, Acevedo J (2017) The influence of physician and patient gender in risk assessment for lung cancer resection. Ann Thorac Surg 104:284\u2013289","journal-title":"Ann Thorac Surg"},{"key":"3607_CR5","doi-asserted-by":"publisher","unstructured":"Gale RP, Saglio G (2021) Point: is there a best duration of deep molecular response to achieve therapy-free remission in chronic myeloid leukaemia? Br J Hematol 192(1):22\u201323. https:\/\/doi.org\/10.1111\/bjh.17112","DOI":"10.1111\/bjh.17112"},{"key":"3607_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.0090","author":"J Gill","year":"2020","unstructured":"Gill J, Haslam A, Crain MS, Herrara-Perez D, Prasad V (2020) Comparison of industry payments in 2017 with annual salary in a cohort of academic oncologists. JAMA Intern Med. https:\/\/doi.org\/10.1001\/jamainternmed.2020.0090","journal-title":"JAMA Intern Med"},{"key":"3607_CR7","doi-asserted-by":"publisher","first-page":"71548","DOI":"10.18632\/oncotarget.17742","volume":"8","author":"DA Goldstein","year":"2017","unstructured":"Goldstein DA, Clark J, Tu Y, Zhang F, Goldstein R, Stemmer SM et al (2017) A global comparison of the cost of patented cancer drugs in relation to global differences in wealth. Oncotarget 8:71548\u201371555","journal-title":"Oncotarget"},{"key":"3607_CR8","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1182\/bloodadvances.2018018614","volume":"2","author":"A Hantel","year":"2018","unstructured":"Hantel A, Larson RA (2018) Imatinib is still recommended for frontline therapy for CML. Blood Adv 2:3648\u20133652","journal-title":"Blood Adv"},{"key":"3607_CR9","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1001\/jama.2020.1012","volume":"323","author":"I Hernandez","year":"2020","unstructured":"Hernandez I, Rodriguez AS, Good C (2020) Changes in list prices, net prices and discounts for branded drugs in the US, 2007\u20132018. JAMA 323:854\u2013862","journal-title":"JAMA"},{"key":"3607_CR10","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 34:966\u201384","journal-title":"Leukemia."},{"key":"3607_CR11","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s00432-016-2158-8","volume":"142","author":"Q Jiang","year":"2016","unstructured":"Jiang Q, Gale RP (2016) Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China. J Cancer Res Clin Oncol 142:1549\u20131555","journal-title":"J Cancer Res Clin Oncol"},{"key":"3607_CR12","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s00432-016-2159-7","volume":"142","author":"Q Jiang","year":"2016","unstructured":"Jiang Q, Liu ZC, Zhang SX, Gale RP (2016) Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia. J Cancer Res Clin Oncol 142:1539\u20131547","journal-title":"J Cancer Res Clin Oncol"},{"key":"3607_CR13","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1007\/s00432-017-2517-0","volume":"143","author":"Q Jiang","year":"2017","unstructured":"Jiang Q, Wang H, Yu L, Gale RP (2017a) Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia. J Cancer Res Clin Oncol 143:2619\u20132630","journal-title":"J Cancer Res Clin Oncol"},{"key":"3607_CR14","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00432-017-2353-2","volume":"143","author":"Q Jiang","year":"2017","unstructured":"Jiang Q, Wang HB, Yu L, Gale RP (2017b) Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy. J Cancer Res Clin Oncol 143:1013\u20131022","journal-title":"J Cancer Res Clin Oncol"},{"key":"3607_CR15","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s00432-018-2594-8","volume":"144","author":"Q Jiang","year":"2018","unstructured":"Jiang Q, Yu L, Gale RP (2018) Patients\u2019 and hematologists\u2019 concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia. J Cancer Res Clin Oncol 144:735\u2013741","journal-title":"J Cancer Res Clin Oncol"},{"key":"3607_CR16","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1182\/blood-2015-06-641043","volume":"126","author":"RA Larson","year":"2015","unstructured":"Larson RA (2015) Is there a best TKI for chronic phase chronic myeloid leukemia? Blood 126:2370\u20132375","journal-title":"Blood"},{"key":"3607_CR17","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jama.2020.0442","volume":"323","author":"FD Ledley","year":"2020","unstructured":"Ledley FD, McCoy SS, Vaughn G, Galkina E (2020) Profitability of large pharmaceutical companies compared with other large public companies. JAMA. 323:834\u2013843","journal-title":"JAMA."},{"key":"3607_CR18","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2015.003640","author":"T Luo","year":"2015","unstructured":"Luo T, Spolverato G, Johnston F, Haider AH, Pawlick TM (2015) Factors that determine cancer treatment choice among minority groups. J Oncol Pract. https:\/\/doi.org\/10.1200\/JOP.2015.003640","journal-title":"J Oncol Pract"},{"key":"3607_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/cncr.32504","volume":"126","author":"K Naqvi","year":"2020","unstructured":"Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yimanez M et al (2020) Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 126:67\u201375","journal-title":"Cancer"},{"key":"3607_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/jnci\/djw003","volume":"108","author":"WV Padula","year":"2016","unstructured":"Padula WV, Larson RA, Dusetzina SB, Apperley JF, Hehlman R, Baccarani M et al (2016) Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States. JNCI 108:3","journal-title":"JNCI"},{"key":"3607_CR21","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1001\/jama.2020.1208","volume":"323","author":"R Rubin","year":"2020","unstructured":"Rubin R (2020) Rebates-The little-known factor behind increasing drug list prices. JAMA. 323:812\u2013813","journal-title":"JAMA."},{"key":"3607_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","volume":"126","author":"S Saussele","year":"2015","unstructured":"Saussele S, Kraus MP, Hehlman R, Lauseker M, Proetel M, Kalmanti L et al (2015) Impact of co-morbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood 126:42\u201349","journal-title":"Blood"},{"key":"3607_CR23","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.mayocp.2015.06.001","volume":"90","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Kantarjian H, Rajkumar SV, Younes A, Zelenetz AD, LeMaistre CA (2015) In support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin Proc 90:996\u20131000","journal-title":"Mayo Clin Proc"},{"key":"3607_CR24","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2020.1166","volume":"323","author":"OJ Wouters","year":"2020","unstructured":"Wouters OJ, McKee M, Luyten J (2020) Estimated research and development investment needed to bring a new medicine to the market, 2009\u20132018. JAMA 323:844\u2013853","journal-title":"JAMA"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03607-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03607-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03607-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T08:10:44Z","timestamp":1635581444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03607-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,22]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3607"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03607-5","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2021,4,22]]},"assertion":[{"value":"28 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"RAL has acted as a consultant or advisor to Novartis, Amgen, Ariad\/Takeda, Astellas, Celgene\/BMS, CVS\/Caremark, Epizyme, and MorphoSys, and has received clinical research support from Novartis, Astellas, Celgene, Cellectis, Daiichi Sankyo, Forty Seven, Rafael Pharmaceuticals, and royalties from UpToDate. RPG is a consultant to: BeiGene Ltd., Fusion Pharma LLC, LaJolla NanoMedical Inc., Mingsight Parmaceuticals Inc., and CStone Pharmaceuticals. Medical Director of FFF Enterprises Inc, on the Board of Directors: RakFond Foundation for Cancer Research Support. Scientific Advisory Board: Antegene Biotech LLC, StemRad Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}